Lipocine (LPCN) risk factors, FY2025 10-K

Risks Relating to Our Business and Industry

1. 01The timelines and costs of our clinical trials may be impacted by numerous factors and any delays may adversely affect our ability to execute our current business strategy
2. 02LPCN 1154 is in development and an NDA submission may not be filed, or if filed, may not be accepted by the FDA66% rewritten
3. 03LPCN 1154 may not achieve planned commercialization or commercialization objectives for a variety of reasons60% rewritten
4. 04There can be no assurance there will not be any third-party patent infringement proceedings against us. Such proceedings could delay or prevent further development of LPCN 1154New
5. 05LPCN 2201 is in a very early stage of development and may not be further developed for a variety of reasons98% rewritten
6. 06LPCN 2101 is in a very early stage of development and may not be further developed for a variety of reasons
7. 07LPCN 2203 is in an early stage of development and may not be further developed for a variety of reasons62% rewritten
8. 08LPCN 2401 is in a very early stage of development and may not be further developed for a variety of reasons44% rewritten
9. 09LPCN 1107 is in a very early stage of development and may not be further developed for a variety of reasons
10. 10Our research and development programs and processes are at an early stage of development, which makes it difficult to evaluate our business and prospects or predict if or when we will successfully commercialize or partner our product candidates
11. 11All of our clinical candidates will be subject to extensive regulation which can be costly and time consuming, cause delays or prevent approval of the products for commercialization
12. 12Preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain FDA approval for their products
13. 13Our business depends, in part, on the commercial success of our licensed product, TLANDO, for royalty revenue and potential milestone payments33% rewritten
14. 14If we fail to obtain adequate healthcare reimbursement for our products, our revenue-generating ability will be diminished and there is no assurance that the anticipated market for our products will be sustained27% rewritten
15. 15Our Licensees’ ability to commercialize TLANDO may be limited46% rewritten
16. 16We will not be able to successfully commercialize our product candidates without establishing sales, marketing and market access capabilities internally or through collaborators
17. 17In order to market any products outside of the United States including South Korea, the GCC countries, and Brazil, our licensees must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy
18. 18We are subject to stringent government regulations concerning the clinical testing of our products and will continue to be subject to government regulation of any product that receives regulatory approval
19. 19The successful commercialization of our product candidates and ability to generate significant revenue will depend on achieving market acceptance
20. 20Even if we obtain marketing approval for our products, physicians and patients using existing products may choose not to switch to our products
21. 21The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted off-label uses, we may become subject to significant liability
22. 22If we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected
23. 23Our future success depends on our ability to retain our chief executive officer and other key executives and to attract, retain and motivate qualified personnel
24. 24Federal legislation and actions by state and local governments may permit re-importation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results37% rewritten
25. 25We may become subject to the risk of product liability claims
26. 26Testosterone is a Schedule III substance under the Controlled Substances Act and any failure to comply with this Act or its state equivalents would have a negative impact on our business
27. 27We may have to dedicate resources to the defense and resolution of litigation
28. 28Cyber security risks and the failure to maintain the integrity of company, employee or clinical data could expose us to data loss, litigation and liability, and our reputation could be significantly harmed

Risks Related to Our Dependence on Third Parties

1. 29We rely upon third-party contractors and service providers for the execution of some aspects of our development programs. Failure of these collaborators to provide services of a suitable quality and within acceptable timeframes may cause the delay or failure of our development programs
2. 30Due to our reliance on CROs or other third parties to assist us or who have historically assisted us in conducting clinical trials, we will be unable to directly control all aspects of our clinical trials
3. 31These factors may materially adversely affect their willingness or ability to conduct our trials in a manner acceptable to us. We may experience unexpected cost increases that are beyond our control
4. 32We and our Licensees rely/will rely on a single supplier for our supply of testosterone esters, the active pharmaceutical ingredient of TLANDO, LPCN 1111, LPCN 2401, and LPCN 1148, and the loss of this supplier could harm our business
5. 33We rely on limited suppliers for our supply of NAS, the active pharmaceutical ingredients of LPCN 1154, LPCN 2201, LPCN 2101, and LPCN 2203 and the loss of these limited suppliers could harm our business
6. 34If we do not establish successful collaborations, we may have to alter our development and commercialization plans for our products

Risks Related to Ownership of Our Common Stock

1. 35Our stock price could decline significantly based on the results and timing of clinical trials, and/or regulatory and other decisions affecting our product candidates
2. 36If we do not maintain effective internal controls over financial reporting in the future, the accuracy and timeliness of our financial reporting may be adversely affected
3. 37We incur significant expenses in order to comply with the requirements of being a public company in the United States
4. 38Our share price is expected to be volatile and may be influenced by numerous factors that are beyond our control
5. 39We may not be able to maintain our listing on the Nasdaq Capital Market, which would adversely affect the price and liquidity of our common stock
6. 40We have no current plans to pay dividends on our common stock and investors must look solely to stock appreciation for a return on their investment in us
7. 41Our management and directors will be able to exert influence over our affairs29% rewritten
8. 42The market price of our common stock has been volatile over the past year and may continue to be volatile
9. 43If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price could decline

Risks Relating to Our Financial Position and Capital Requirements

1. 44We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations
2. 45Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights
3. 46We cannot predict when we will generate product revenues and may never achieve or maintain profitability
4. 47We have incurred significant operating losses in most years since our inception and anticipate that we will incur continued losses for the foreseeable future49% rewritten
5. 48Our operating results may fluctuate significantly, and any failure to meet financial expectations may disappoint securities analysts or investors and result in a decline in the price of our securities

Risks Relating to Our Intellectual Property

1. 49Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection
2. 50If we do not obtain additional protection under the Drug Price Competition and Patent Term Restoration Act and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidates, our business may be materially harmed
3. 51We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights to our products and technology
4. 52If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business
5. 53Although we own worldwide rights to our product candidates, we do not have patent protection for the product candidates in a significant number of countries, and we will be unable to prevent infringement in those countries
6. 54Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 55We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers